Physician profile
Rakesh Vadde
NPI 1366680845
$3,504.10
in general payments reported to CMS, 2019-2025
17 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,044 · 2022: $681 · 2023: $924 · 2024: $597 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Travel and Lodging: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.74 |
| Travel and Lodging | $388.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $2,303.01 | 2021-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Glaxosmithkline, LLC. | $386.77 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $188.72 | 2023-2024 | Airsupra, Breztri, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $133.30 | 2022-2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $73.61 | 2023-2024 | Dupixent |
| Genzyme Corporation | $61.41 | 2023-2024 | |
| La Jolla Pharmaceutical Company | $54.78 | 2024 | Giapreza |
| Ani Pharmaceuticals, INC. | $50.23 | 2024-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $45.47 | 2023-2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $44.47 | 2023-2024 | |
| Intuitive Surgical, INC. | $37.00 | 2025 | |
| Viatris Specialty LLC | $32.29 | 2025 | Yupelri |
| United Therapeutics Corporation | $22.15 | 2024 | Tyvaso |
| Genentech USA, INC. | $20.62 | 2023 | Xolair |
| Verona Pharma, INC. | $19.50 | 2025 | Ohtuvayre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $17.42 | 2025 | |
| Amgen INC. | $13.35 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Vadde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.